Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo

The Journal of Infectious Diseases(2023)10.1093/infdis/jiad507Source: DataRank Database

HIV Prevention Among Men Who Have Sex With Men: Tenofovir Alafenamide Combination Preexposure Prophylaxis Versus Placebo is a research paper published in The Journal of Infectious Diseases (2023). On theSindex it has a DataRank of 0.168. It has been cited 2 times, with 2 citing works in its 1-hop citation network.

N/A

0.168DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access2 citations · 2 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02842086 NCT00458393

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)Impact (FWCI 0.33)OA: greenTopics (59)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 98%Citation Network 2%

Base Score Contribution

0.165

From this paper's citation signal

Citation Network Contribution

3.51 × 10⁻³

From 1 citing papers with measurable signal

Learn more about DataRank methodology →

Top 2 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 2 citers.

Keep asking: What do I want? What do I have? What do I do?
European Journal of Epidemiology20251 citations168 referencesContributes 0.004
Pre-exposure Prophylaxis Outcomes in High-Risk Individuals in Saudi Arabia: A 48-Week Observational Cohort Study
Cureus20260 citations30 referencesContributes 0.000

Authors (10)

Stephen R. Cole ORCID,Jessie K. Edwards ORCID,David V. Glidden ORCID,Moupali Das ORCID,Bonnie E. Shook‐Sa ORCID

Live enrichment

PubMed:37969014 PMC:PMC11011171 OpenAlex:https://openalex.org/W4388737347

National Institute of Allergy and Infectious Diseases

Grant: R01-AI157758

National Institute of Allergy and Infectious Diseases

Grant: T32-AI007001

National Institute of Allergy and Infectious Diseases

Grant: P30-AI50410

of Acquired Immunodeficiency Syndrome

Grant: R01-AI062333

NIH

Grant: U01-AI64002

NIAID NIH HHS

Grant: R01 AI062333

NIAID NIH HHS

Grant: R01 AI143357

NIAID NIH HHS

Grant: R01 AI157758

NIAID NIH HHS

Grant: P30 AI050410

NICHD NIH HHS

Grant: T32 HD091058

NIAID NIH HHS

Grant: U01 AI064002

National Institutes of Health

Grant: 5T32AI007001-17

TRAINING IN SEXUALLY TRANSMITTED DISEASES AND AIDS

National Institutes of Health

Grant: 5R01AI157758-05

Improved analysis of experiments and observational studies in HIV

National Institutes of Health

Grant: 5P30AI050410-05

UNC Center for Aids Research

National Institutes of Health

Grant: 5R01AI062333-05

Chemoprophylaxis and HIV-Host Interactions

National Institutes of Health

Grant: 5U01AI064002-06

Chemoprophylaxis for HIV Prevention in Men

Division

Gilead Sciences

Bill and Melinda Gates Foundation

FWCI

0.33

Citation Percentile

0.6%

Influential Citations

Citation Trend

2025

2026

greenLicense: OUP Standard Publication Reuse

repositoryhttps://escholarship.org/content/qt3vz0p8m5/qt3vz0p8m5.pdf

publisherhttps://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad507/53971507/jiad507.pdf

publisherhttps://academic.oup.com/jid/article-pdf/229/4/1123/57223203/jiad507.pdf

repositoryhttps://escholarship.org/uc/item/3vz0p8m5

Fields of Study

HIV/AIDS Research and InterventionsHIV-related health complications and treatmentsHIV/AIDS drug development and treatmentMedicine0303 health sciences03 medical and health sciencesHumansMaleAdenineAnti-HIV AgentsEmtricitabineHIVHIV InfectionsHomosexuality, MalePre-Exposure ProphylaxisSexual and Gender MinoritiesTenofovir

MeSH Terms

EmtricitabineTenofovirSexual and Gender MinoritiesAdenineHIVHumansMaleHIV InfectionsHomosexuality, MaleAnti-HIV AgentsPre-Exposure Prophylaxis

Keywords

EmtricitabineTenofovir alafenamideMedicinePlaceboPre-exposure prophylaxisPopulationInternal medicineConfidence intervalHuman immunodeficiency virus (HIV)Men who have sex with menViral loadImmunologyAntiretroviral therapyPathologyEnvironmental healthAlternative medicineHIVTenofovirPrepIndirect ComparisonsCounterfactual PlaceboBridged ComparisonMaleAnti-HIV AgentsAdenine610HIV InfectionsHomosexualitySexual and Gender MinoritiesHumansHomosexuality, Male

Sustainable Development Goals

SDG 0: Good health and well-being